Kite Pharma (KITE) Given News Sentiment Score of 0.22
Media headlines about Kite Pharma (NASDAQ:KITE) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kite Pharma earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.7341715668319 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Kite Pharma (NASDAQ:KITE) traded up $0.20 during mid-day trading on Monday, reaching $179.99. 100 shares of the company’s stock traded hands, compared to its average volume of 1,652,408. The firm has a market cap of $10,280.00 and a price-to-earnings ratio of -26.09. Kite Pharma has a 52 week low of $39.82 and a 52 week high of $179.99.
TRADEMARK VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://theolympiareport.com/2018/01/01/kite-pharma-kite-given-news-sentiment-score-of-0-22.html.
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.